| Year | Title | Author(s) |
|---|
| 2016 |
Mitochondrial fission - a drug target for cytoprotection or cytodestruction?
Pharmacol. Res. Perspect. |
Rosdah, AA Holien, JK Delbridge, LMD Dusting, GJ Lim, SY |
| 2016 |
Harnessing the secretome of cardiac stem cells as therapy for ischemic heart disease
Biochem. Pharmacol. |
Khanabdali, R Rosdah, AA Dusting, GJ Lim, SY |
| 2017 |
Mdivi-1 Protects Human W8B2(+) Cardiac Stem Cells from Oxidative Stress and Simulated Ischemia-Reperfusion Injury
Stem Cells Dev. |
Rosdah, AA Bond, ST Sivakumaran, P Hoque, A Oakhill, JS Drew, BG Delbridge, LMD Lim, SY |
| 2020 |
New perspectives on the role of Drp1 isoforms in regulating mitochondrial pathophysiology
Pharmacology & Therapeutics |
Rosdah, AA Smiles, WJ Oakhill, JS Scott, JW Langendorf, CG Delbridge, LMD Holien, JK Lim, SY |
| 2022 |
Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission
Cardiovascular Research |
Kalkhoran, SB Kriston-Vizi, J Hernandez-Resendiz, S Crespo-Avilan, GE Rosdah, AA Lees, JG Da Costa, JRS Ling, NXY Holien, JK Samangouei, P Chinda, K Yap, EP Riquelme, JA Ketteler, R Yellon, DM Lim, SY Hausenloy, DJ |